Stake logo


REVOLUTION Medicines Inc

About RVMD

Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The company’s research and development (R&D) pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. Its RAS(ON) Inhibitors in development include RMC-6236, RMC-6291, RMC-9805 and RMC-8839, and a pipeline of research compounds targeting additional RAS variants. The RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1). The Company’s tri-complex technology enables to discover small molecule inhibitors of targets lacking intrinsic drug binding sites by inducing new druggable pockets.

Buy US stocks in Australia starting with RVMD. Open an account and start investing today!

Market Capitalisation


Price-earnings ratio


Dividend yield




High today


Low today


Open price


52-week high


52-week low



One share of REVOLUTION Medicines Inc is valued at $27.64.

The ticker symbol for REVOLUTION Medicines Inc is RVMD.

To buy RVMD stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in RVMD

As of 28/01/2023 REVOLUTION Medicines Inc has a market cap of $2.5B.

The REVOLUTION Medicines Inc 52-week high stock price is $31.37.

The REVOLUTION Medicines Inc 52-week low stock price is $14.08.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.